United States Últimas notícias

UniFirst (NYSE:UNF) shareholders voted decisively to approve the company’s pending acquisition by Cintas (NASDAQ:CTAS) during a special meeting.

"Not being invested is actually you're greatest risk," KKR Partner Alisa Wood tells Bloomberg's Anna Edwards and Tom Mackenzie. Wood spoke on 'Bloomberg: The Opening Trade'. This interview occurred on Tuesday, June 9.

Cogent Biosciences (NASDAQ:COGT) announced detailed clinical results from its registration-directed APEX trial evaluating its investigational precision therapy, bezuclastinib, in patients with advanced systemic mastocytosis (AdvSM).

Independent Bank (NASDAQ:IBCP) secured key regulatory approvals required to complete its previously announced acquisition of HCB Financial, the parent company of Highpoint Community Bank.

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced top-line results from the Phase 3 LAGOON clinical trial evaluating Zepzelca (lurbinectedin) in patients with relapsed, second-line metastatic small cell lung cancer (SCLC).

Baidu (NASDAQ:BIDU) announced that AmiGo, an on-demand autonomous mobility service developed through its Apollo Go intelligent driving division in partnership with Swiss Post's PostBus, has secured a special operating permit from Switzerland’s Federal Roads Office (FEDRO) for highly automated (Level 4) operations.

SharonAI Holdings (NASDAQ:SHAZ) announced a major six-year strategic compute collaboration with NVIDIA (NASDAQ:NVDA) to massively scale sovereign artificial intelligence infrastructure across Australia.

MBX Biosciences (NASDAQ:MBX) announced detailed results from its 12-week Avail Phase 2 clinical trial and new one-year data from an ongoing open-label extension study evaluating its investigational endocrine therapy, canvuparatide.

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported new clinical trial data and supportive real-world evidence evaluating its hereditary angioedema (HAE) portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Annual Meeting in Istanbul, Turkey.

If Switzerland votes to cap the population at 10 million inhabitants, this could severely impact labor-intensive sectors like restaurants, construction, and healthcare, as well as innovative sectors like scientific research and product development, all of which depend 'heavily' on foreign workers, says Rudolf Minsch, Chief Economist at Swiss business sector umbrella organization Economiesuisse. He spoke on 'The Pulse with Francine Lacqua' on Bloomberg TV.

Kymera Therapeutics (NASDAQ:KYMR) reported positive findings from its Phase 1 clinical trial evaluating KT-621, a first-in-class oral small molecule STAT6 degrader, in healthy Japanese adults.

Pierre Ferragu managing director at New Street Research, discusses the record-breaking SpaceX IPO, his growth and capex expectations for the company moving forward, and the "Musk premium" factored into its valuation.